Edge Therapeutics, Inc., a clinical-stage biotechnology company developing novel hospital-based therapies in the management of acute, life-threatening conditions, announced the closing of a $20 million dual-tranche term loan with Hercules Capital, Inc. The term loan will be used to refinance existing debt and for general corporate purposes.

An initial $15 million was drawn down at closing, with an additional $5 million available, at Edge’s option, through June 15, 2017. The term loan will mature on February 3, 2020.

“We are pleased to announce this new loan facility, which increases our cash position at an attractive cost of capital, enabling us to continue investing in our pipeline and executing our corporate growth strategy,” said Andrew Einhorn, Chief Financial Officer of Edge. “Importantly, we believe that this credit facility will strengthen our financial position at the anticipated completion of the pivotal, Phase 3 NEWTON 2 study of our lead therapy EG-1962 for the treatment of aneurysmal subarachnoid hemorrhage.”

"Hercules is pleased to extend and expand our financing partnership with Edge at this important stage to allow them to continue to advance their pipeline and achieve their growth objectives," said Scott Bluestein, Chief Investment Officer at Hercules Capital. “This further investment in Edge exemplifies our steadfast principle of being there to support our portfolio companies through multiple stages of development.” 

Edge Therapeutics, Inc. is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological conditions. EG-1962, Edge’s lead product candidate, has the potential to fundamentally improve patient outcomes and transform the management of aneurysmal subarachnoid hemorrhage, or aSAH, which is bleeding around the brain due to a ruptured brain aneurysm.

Hercules Capital, Inc. is a leading specialty finance company focused on providing senior secured venture growth loans to high-growth, innovative venture capital-backed companies in a broad variety of technology, life sciences and sustainable and renewable technology industries. Since inception (December 2003), Hercules has committed more than $6.0 billion to over 350 companies and is the lender of choice for entrepreneurs and venture capital firms seeking growth capital financing.